Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. AZN
4. SPY
5. CRCL
6. V
7. GE
8. ASML
9. SPIR
10. NVDA

Go back to Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy
SAREPTA THERAP (NASDAQ: SRPT) Delayed: 22.50 --0 (-0%)
Previous Close $22.50    52 Week High $63.73 
Open $22.50    52 Week Low $8.00 
Day High $22.50    P/E N/A 
Day Low $22.50    EPS $-5.69 
Volume 211,339